# Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

> **NCT03061331** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 20 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** LUM/IVA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03061331
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2017-09-06
- **Final completion:** 2017-10-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061331, "Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03061331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*